Kisqali (ribociclib)

@stolaney1, ASCO 2023💫: Highlights from the NATALEE trial of ribociclib and endocrine therapy in the treatment of breast cancer. https://t.co/L7sdlObWex (@DFCI_BreastOnc)

It’s really a shame if @AnthemBCBS is not approving ribociclib for 1st line metastatic ER+HER2- breast cancer. (@FelipeBatalini)

Check out Dr. Nagi El Saghir @NagiSaghir @AUB_Lebanon discussing #ASCO23 Outcomes w/1st Line Ribociclib + Endocrine Tx vs. PC Combination Chemo by Age in Pre/Perimenopausal Pts w/ Aggressive HR+/HER2− Adv. BC: RIGHT Choice Trial Subgroup Analysis" #bcsm https://t.co/O7V5ZSkNlg (@Sameh_VuMedi)

🎥@PTarantinoMD of @DanaFarber highlights breast cancer updates at #ASCO23. Exciting results from NATALEE trial show ribociclib + endocrine therapy benefiting early breast cancer patients. Also discusses ADC sequencing in #BreastCancer: ➡️https://t.co/cZCZ44Kedb #ASCO23 #BCSM (@VJOncology)

#ASCO23 #BreastCancer #OncoAlert Take Home Message 1. CDK series. NATALEE: Adjuvant Ribociclib (400mg/day) improves 3-year PFS by 3% (HR: 0.748). Need more follow-up. monarchE: Comparison of ≥65 and <65 age groups. Similar efficacy and side effects. Higher discontinuation rate… https://t.co/ZRL6nsHFOY (@teamoncology)

#ASCO23 #BreastCancer #OncoAlert Take Home Message 1. CDK series. NATALEE: Adjuvant Ribociclib (400mg/day) improves 3-year PFS by 3% (HR: 0.748). Need more follow-up. monarchE: Comparison of ≥65 and <65 age groups. Similar efficacy and side effects. Higher discontinuation rate… https://t.co/Moi2bw2jcm (@teamoncology)

#ASCO23 #BreastCancer #OncoAlert Take Home Message 1. NATALEE: Adjuvant Ribociclib (400mg/day) improves 3-year PFS by 3% (HR: 0.748). Need more follow-up. monarchE: Comparison of ≥65 and <65 age groups. Similar efficacy and side effects. Higher discontinuation rate in ≥65… https://t.co/JHYMXeE0nG (@teamoncology)

#ASCO23 #BreastCancer #OncoAlert Take Home Message 1. NATALEE: Adjuvant Ribociclib (400mg/day) improves 3-year PFS by 3% (HR: 0.748). Need more follow-up. monarchE: Comparison of ≥65 and <65 age groups. Similar efficacy and side effects. Higher discontinuation rate in ≥65… https://t.co/LeVkLQGGNN (@teamoncology)

Lisa A. Carey, MD, and Dennis J. Slamon, MD, PhD, on Early Breast Cancer: Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy https://t.co/x9z6xTK0fm #bcsm #breastcancer #oncology #ASCO23 @DrLisaCarey @UNC_Lineberger @UCLAHealth (@ASCOPost)

Excellente analysis #ASCO2023 #ribociclib #breastcancer (@DrSoukayna)

Interesting to find, after #ASCO23, what #breastcancer #patients make of 3% absolute reduction in relapse risk with #adjuvant #ribociclib. Can we pick winners based on #biomarkers? (@drmcopeman)

Adjuvant Ribociclib And Endocrine Therapy In Patients With HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial by Dr. @gandhi_shipra of @RoswellPark https://t.co/vM9OYxvLni @DipeshUpretyMD @samsara_medico #ASCO23 #bcsm (@BTFCancerNews)

The addition of ribociclib to endocrine therapy extended invasive DFS for patients with hormone receptor-positive, HER2-negative early-stage breast cancer #ASCO23 @UCLAJCCC @MDAndersonNews @NovartisCancer @DrDebuTripathy #Kisqali #NATALEE https://t.co/je2JJdsf0t (@HemOncToday)

📢 @hoperugo shares what to look forward to at #ASCO23 in #BreastCancer! Exciting updates on capivasertib in CAPItello-291 trial and NATALEE trial investigating ribociclib in adjuvant treatment. ➡️https://t.co/P0c5qlXuCe⬅️ Stay tuned with https://t.co/ys1d8pDAKO! @ASCO #BCSM (@VJOncology)

I would add results of the NATALEE study (adjuvant ribociclib) for early stage #breastcancer. #ASCO23 #bcsm (@drteplinsky)

Frontline ribociclib + letrozole prolonged OS over letrozole alone in a subset of pts w/ HR+/HER2– advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy. @BCJoyceO @bswhealth #bcsm #oncology https://t.co/Mzv5blztJZ (@OncLive)

Frontline ribociclib + letrozole prolonged OS over letrozole alone in a subset of pts w/ HR+/HER2– advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy. @BCJoyceO @bswhealth #bcsm #oncology https://t.co/Lob3anHN8i (@OncLive)

The results of @GOG 3026 presented at #SGO2023. #Ribociclib & #Letrozole Has Activity in Recurrent Low-Grade Serous Ovarian Cancer. From @VuMedi. @kisqali_us #clinicaltrial #ovariancancer #oncology #SGOmtg #gyncsm The GOG Founda…https://t.co/WbDTstiRBI https://t.co/Uu5Vk4A1uJ (@dsmgyo)

My latest video about the CDK inhibitors Palbociclib, Ribociclib, Abemaciclib (Ibrance, Kisqali and Verzenio) and Breast Cancer https://t.co/9aKS2qOaT2 via @YouTube (@Liz_ORiordan)

This trial led by Dr. Hortobagyi from @MDAndersonNews published at @NEJM was one of the top advances in breast cancer treatments -->Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer @OncoAlert #ACSchat @JournalCancer @weoncologists @RamalingamMD… https://t.co/lgNsOPnRIE (@VivekSubbiah)

Full text link --> Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM #ACScancerchat https://t.co/gYyP1zhsDX (@VivekSubbiah)

Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer https://t.co/9Ou9tf5DCE via @YahooFinance (@DrFaridSaleh)

Ribociclib combine with endocrine therapy decrease #recurrences in #patients with high risk HR+/HER2- early #breastcancer @Novartis @mybsmo #bcsm #OncoAlert https://t.co/w5T0BaaF3k (@E_de_Azambuja)

Phase III NATALEE trial (with Ribociclib) meets primary endpoint iDFS demonstrating benefit in patients with stage II/III HR+/HER2- breast cancer | ⁦@Novartis⁩ ⁦@OncLive⁩ ⁦@ASCO⁩ ⁦@myESMO⁩ ⁦@AACR⁩ ⁦@DFCI_BreastOnc⁩ https://t.co/CgRG5qcfIh (@DrChoueiri)

Interesting press release. Second cdk46 now showing benefit in adjuvant setting. #ribociclib to be given for 3 yrs instead of #abemaciclib for 2. Differences between Natalee and MonarchE. Lower risk population in Natalee. #bcsm (@VKaklamani)

Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: results from the prospective BioItaLEE trial https://t.co/1qdrIoP8b8 So proud to be part of this! TKI is a very promising, low cost biomarker! (@FilippoMontemu1)

🎥 @LoiblSibylle of @GBG_Forschung talks on AMICA: Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancer Watch: 👉https://t.co/ZzjgcouqPb👈 @SABCSSanAntonio #SABCS22 #BCSM #BreastCancer (@VJOncology)

2. Adjuvant CDK4/6i in HR+/HER2- breast cancer: - Abemaciclib (monarchE): ⬇️ risk of iDFS & DRFS; approved - Palbociclib (PALLAS): no benefit - Ribociclib (NATALEE): ongoing a. Are all CDK 4/6i the same? @oreganruth  b. How do you manage Abema's AE? @drteplinsky @JAMouabbi (@OncBrothers)

Feel good & honored to have our #RightChoice study positive results presented in both Dr Dan Hayes @hoosierdfh & @oreganruth discussions at #SABCS22: #Ribociclib + ET superior to Combo Chemo in 1L therapy pts w HR+ HER2- (& aggressive) metastatic breast cancer @OncoAlert (@NagiSaghir)

What to do beyond progression on CDK4/6i 📌 PACE continued palbociclib and MAINTAIN switched to ribociclib. Maintain showed imp in mPFS 📌 PACE evaluated the addition of CKI. ? Signal towards imp in OS #SABCS2022 @OncoAlert (@MridulaGeorgeMD)

Phase 2 PACE trial presented by @elmayermd Palbociclib + fulvestrant after prior CDK4/6i did not improve PFS vs fulvestrant alone. Addition of avelumab (PD-L1i) prolonged PFS. Interesting contrast with MAINTAIN where ribociclib after prior CDK4/6i was beneficial. #SABCS2022 (@CancerNetwrk)

生命を脅かす内臓転移がある、進行が速いまたは強い症状があるような悪性度の高いホルモン受容体陽性HER2陰性の閉経前/閉経周辺期の進行 #乳がん の1次治療には、2剤併用化学療法よりも #ribociclib と内分泌療法の併用の方が有効な可能性が報告されました。 #SABCS22 https://t.co/2KdNStuIth (@cancer_navi)

#SABCS2022 Treatment with ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal patients with aggressive HR+/HER2– advanced breast cancer: Primary results from the RIGHT Choice trial (PHASE II) (@MLPOncoData)

For premenopausal patients with aggressive HR +ve/Her2 -ve breast cancer, first-line ribociclib plus endocrine therapy may be more effective than combination chemotherapy- phase II RIGHT Choice trial (@drkpavithran)

Enlightening results of the RIGHT Choice study: first-line ribociclib is a clinically meaningful and better tolerated treatment option in patients with HR+/HER2− advanced #BreastCancer, with respect to chemotherapy. #SABCS22 #bcsm (@LGerratana)

RIGHT Choice study - CDK4/6i + ET vs combination CT in young ABC #BreastCancer with aggressive disease mPFS was approximately doubled in the ribociclib arm compared with the CT arm (24 vs 12.3 mo) #SABCS22 @OncoAlert #OncoAlert (@Icro_Meattini)

Presented at #SABCS22 results from #RIGHT trial on #ribociclib + endocrine therapy vs. chemotherapy as first-line therapy in metastatic aggressive HR+/HER2- #BreastCancer: very very important data to STOP using #chemotherapy in this setting ! @OncoAlert #bcsm @SABCSSanAntonio (@matteolambe)

Are you still using chemo for "aggressive" HR+ mBC? Based on the RIGHT Choice study we should not! Patients treated with CDK4/6i (#Ribociclib) + ET had better PFS ORR and CBR compared to those treated with chemo! #SABCS22 #EndCancer #bcsm @OncoAlert @SABCSSanAntonio @NagiSaghir https://t.co/4j3lIArru4 (@JAMouabbi)

Are you still using chemo for "aggressive" HR+ mBC? Based on the RIGHT Choice study we should not! Patients treated with CDK4/6i (#Ribociclib) + ET did better PFS ORR and CBR compared to those treated with chemo! #SABCS22 #EndCancer #bcsm @OncoAlert @SABCSSanAntonio @NagiSaghir (@JAMouabbi)

PD17-07 Friday @SABCSSanAntonio Cell-cycle inhibition and immune microenvironment in HR+/HER2- breast cancer during and after preoperative ribociclib and letrozole vesus chemotherapy: A correlative analysis of the 1402-SOLTI/CORALLEEN phase 2 trial Presenter: @TomasPascualMD (@prat_aleix)

COMPLEEMENT-1 of 1st line ribociclib and letrozole in HR+/HER2- MBC included 51 brain metastases pts. Time to progression similar in CNS group vs All pts. Intracranial endpoints not reported. (Cottu, The Breast 2022) #bcsm https://t.co/kzlJpspulI (@drsarahsam)

#PostTest Q2️⃣ #CME #TumorBoardTuesday 👉🏽Free CME🔗: https://t.co/7sDmd4BRzd 👨🏽‍🦳Male who has stage 4 (M1) #BreastCancer with tumor HR+/HER2- & PIK3CA mutation, previously tried aromatase inhibitor + a GnRH analog + ribociclib. 🧐What therapy would YOU recommend? (@JasmineSukumar)